Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma

Abstract

Background: Patients with refractory or relapsed multiple myeloma are considered to have a very poor prognosis, and new regimens are needed to improve this setting. Pomalidomide is a new immunomodulatory drug with high in vitro potency. Immunomodulatory drugs are hypothesized to act through multiple mechanisms. Here we performed a systemic analysis to evaluate pomalidomide-based chemotherapy (pomalidomide in combination with low-dose dexamethasone) as salvage treatment for patients with refractory and relapsed multiple myeloma. Methods: Clinical studies evaluating the efffectiveness of pomalidomide based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: For pomalidomide based regimens, 4 clinical studies which including 291 patients with refractory and relapsed multiple myeloma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 41.2% (120/291). Major adverse effects were hematologic toxicity, including grade 1 or 2 anemia, leucopenia and thrombocytopenia with pomalidomide based treatment. No treatment related death occurred. Conclusion: This pooled analysis suggests that pomalidomide in combination with low-dose dexamethasone is active with good tolerability in treating patients with refractory or relapsed multiple myeloma.

Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center

“…Symptomatic multiple myeloma (MM) is a clonal malignant neoplasm of plasma cells originating in the bone marrow with the median survival of ~4 years (Sun et al, 2015;Landgren et al, 2009). As per United States surveillance and epidemiology multiple myeloma accounts for 1% of overall malignancies and approximate 10% of all hematopoietic malignancies (Rajkumar., 2011;Vincent., 2014 (Sutandyo et al, 2015).…”

Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple

“…La pomalidomida parece ser más potente que la talidomida y la lenalidomida con respecto a la coestimulación de células T 42,43. Aunque el tratamiento con pomalidomida se ha traducido en un aumento significativa de la supervivencia en MM, el mecanismo de acción en lo que se refiere a la modulación inmune no se conoce por completo. En el futuro, el diseño de combinaciones terapéuticas óptimas con pomalidomida depende de una mayor comprensión de sus diversos mecanismos inmunomoduladores 47 .…”

International Scoring System in Symptomatic Multiple Myeloma: Experience from a Tertiary Care Center

“…It accounts for approximately 1% of all neoplastic diseases and 13% of hematopoietic malignancies (Rajkumar., 2011;Vincent., 2014). The median age at diagnosis is approximately 70 years with the median survival of 4 years (Sun et al, 2015;Mehdi et al, 2013;Wang et al, 2015).…”